| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | IGA; MB-1 |
| Entrez GeneID | 973 |
| clone | 4A10D12 |
| WB Predicted band size | 25kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD79A (AA: extra(33-143)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于LOXL4抗体的3篇参考文献及其简要摘要：
1. **"A novel monoclonal antibody targeting LOXL4 inhibits tumor growth in triple-negative breast cancer"**
*Authors: Smith A, et al.*
**摘要**: 该研究开发了一种靶向LOXL4的单克隆抗体，证实其在三阴性乳腺癌模型中通过抑制LOXL4介导的细胞迁移和侵袭，显著减缓肿瘤生长，提示其作为潜在治疗工具的可行性。
2. **"LOXL4 expression and its clinical relevance in pancreatic cancer: An immunohistochemical study"**
*Authors: Chen L, et al.*
**摘要**: 利用特异性抗LOXL4抗体进行免疫组化分析，发现LOXL4在胰腺癌组织中高表达，且与患者预后不良相关，表明其可能作为胰腺癌的生物标志物或治疗靶点。
3. **"LOXL4 antibody-based inhibition of fibrotic remodeling in cardiac disease"**
*Authors: Park J, et al.*
**摘要**: 研究通过LOXL4中和抗体阻断纤维化通路，证明其在心脏纤维化模型中可减少胶原交联和心肌重塑，为治疗纤维化相关心脏病提供了实验依据。
(注：以上文献为示例，实际引用时需根据真实文献调整信息。)
Lysyl oxidase-like 4 (LOXL4) is a member of the lysyl oxidase (LOX) family, which comprises copper-dependent enzymes critical for extracellular matrix (ECM) remodeling. These enzymes catalyze the crosslinking of collagen and elastin by oxidizing lysine residues, thereby maintaining tissue integrity and biomechanical properties. Unlike other LOX family members (LOX, LOXL1-3), LOXL4 exhibits distinct structural features, including a unique propeptide region, and is implicated in both physiological processes and pathological conditions. It is expressed in various tissues, with roles in development, wound healing, and angiogenesis.
LOXL4 has gained attention for its dual role in cancer progression. While it can suppress primary tumor growth by modulating ECM stiffness and cell adhesion, it also promotes metastasis by enhancing epithelial-mesenchymal transition (EMT) and facilitating tumor cell invasion. Dysregulated LOXL4 expression is associated with cancers (e.g., breast, gastric, colorectal) and fibrotic diseases. Its involvement in immune evasion through ECM-mediated T-cell suppression further highlights therapeutic relevance.
LOXL4 antibodies are essential tools for detecting protein expression, localization, and functional studies. They enable investigations into LOXL4's molecular mechanisms, including its interaction with signaling pathways (e.g., TGF-β, HIF-1α) and ECM components. Researchers utilize these antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore LOXL4's diagnostic potential and validate its role as a therapeutic target. Inhibiting LOXL4 with monoclonal antibodies or small molecules is being explored to counteract metastasis and fibrosis, though challenges in specificity and tissue selectivity remain.
×
